Citations 131

Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis

Aging | July 8, 2020 | Volume: 12 | Issue: 14 | Pages: 15134-15156

10.18632/aging.103612 | PMID 32640422

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

Neurology | June 18, 2020 | Volume: 95 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000009758 | PMID 32554760

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD

Neurology Neuroimmunology & Neuroinflammation | May 28, 2020 | Volume: 7 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000727 | PMID 35413004

Pathological findings in central nervous system demyelination associated with infliximab

Multiple Sclerosis Journal | December 17, 2019 | Volume: 26 | Issue: 9 | Pages: 1124-1129

10.1177/1352458519894710 | PMID 31845616

Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.
Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain

JCI Insight | September 18, 2019 | Volume: 4 | Issue: 18 | Pages: No page available

10.1172/jci.insight.130681 | PMID 31534057

Insulin resistance associates with increased risk for cognitive decline and dementia; however, the underpinning mechanisms for this increased risk remain to be fully defined. As insulin resistance impairs mitochondrial oxidative metabolism and increases ROS in skeletal muscle, we considered whether similar events occur in the brain, which — like muscle — is rich in insulin receptors and mitochondria. We show that high-fat diet–induced (HFD-induced) brain insulin resistance in mice decreased mitochondrial ATP production rate and oxidative enzyme activities in brain regions rich in insulin receptors. HFD increased ROS emission and reduced antioxidant enzyme activities, with the concurrent accumulation of oxidatively damaged mitochondrial proteins and increased mitochondrial fission. Improvement of insulin sensitivity by both aerobic exercise and metformin ameliorated HFD-induced abnormalities. Moreover, insulin-induced enhancement of ATP production in primary cortical neurons and astrocytes was counteracted by the insulin receptor antagonist S961, demonstrating a direct effect of insulin resistance on brain mitochondria. Further, intranasal S961 administration prevented exercise-induced improvements in ATP production and ROS emission during HFD, supporting that exercise enhances brain mitochondrial function by improving insulin action. These results support that insulin sensitizing by exercise and metformin restores brain mitochondrial function in insulin-resistant states.
Phosphodiesterase 10A IgG

Neurology | July 17, 2019 | Volume: 93 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000007971 | PMID 31315972

Using germline variants to estimate glioma and subtype risks

Neuro-Oncology | January 8, 2019 | Volume: 21 | Issue: 4 | Pages: 451-461

10.1093/neuonc/noz009 | PMID 30624711

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody

JAMA Neurology | December 21, 2018 | Volume: 76 | Issue: 3 | Pages: 301

10.1001/jamaneurol.2018.4053 | PMID 30575890

Paraneoplastic neuronal intermediate filament autoimmunity

Neurology | October 3, 2018 | Volume: 91 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000006435 | PMID 30282771

Population-based study of “no evident disease activity” in MS

Neurology Neuroimmunology & Neuroinflammation | September 11, 2018 | Volume: 5 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000495 | PMID 30211251